key: cord-0824695-kwck6dx3
authors: Liang, Chih-Kuang; Lee, Wei-Ju; Peng, Li-Ning; Meng, Lin-Chieh; Hsiao, Fei-Yuan; Chen, Liang-Kung
title: COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy-Making
date: 2022-03-21
journal: Clin Geriatr Med
DOI: 10.1016/j.cger.2022.03.006
sha: d1fb1f739231eb16a13889f54ce28a684b2aa9b8
doc_id: 824695
cord_uid: kwck6dx3

The COVID-19 pandemic has strong adverse impacts on vulnerable populations, such as frail older adults. The success of COVID-19 vaccine development, together with extensive global public health efforts (face masks, hand hygiene, lockdowns and many others), brought a glimmer of hope to the control of the COVID-19 pandemic. Nevertheless, challenges in COVID-19 vaccine development and vaccination strategies among older people remain still. In this article, some previous examples regarding vaccination in older adults, including influenza, herpes zoster, and pneumococcal pneumonia, have been reviewed for comparisons. This article further conducts comparisons between different COVID-19 vaccine platforms based on their technology, production requirement, immune response, advantages and disadvantages. Efficacy and safety of COVID-19 vaccines in frail older people in long-term care settings have been reviewed. Challenges of COVID-19 vaccine development and policy-making for vaccination strategies in older adults have been addressed.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 and was declared a global pandemic on March 11, 2020, by the World Health Organization (WHO). By the end of 2021, there were 288,306,329 confirmed cases and 5,438,835 COVID-19-related deaths according to the WHO Coronavirus Dashboard 1 . The COVID-19 pandemic has substantially impacted healthcare systems and societies across the world, and this impact will last longer than expected. Public health crises such as the COVID-19 pandemic and extreme weather have strong adverse impacts on vulnerable populations, such as children, the disadvantaged, frail older adults, and people with disability or dementia 2, 3, 4, 5 . Studies have clearly shown the vulnerability of these populations when encountering a public health crisis, e.g., earthquakes, extreme weather and pandemics, and special attention and care plans are needed to tackle these challenges 6 . Older people are generally considered a high-risk population in clinical services because they are more likely to present atypical symptoms, multimorbidity, geriatric syndromes, functional limitations, and unexpected clinical outcomes 7,8 . The knowledge and clinical experiences in the treatment of older people with acute illnesses can be applied to the COVID-19 pandemic. A recent systematic review and meta-analysis included 13,624 older J o u r n a l P r e -p r o o f patients with COVID-19 and identified that approximately half of older patients with COVID-19 had severe cases, one-fifth were critically ill, and one-tenth died 9 . Due to their higher disease severity and mortality risk, older people have become the priority in COVID-19 vaccination programs.

The success of COVID-19 vaccine development, together with extensive global public health efforts (face masks, hand hygiene, lockdowns and many others), brought a glimmer of hope to the control of the COVID-19 pandemic. All countries started their vaccination plans based on the availability and access to vaccines, and most countries prioritized older adults and nursing home residents for vaccination due to their higher risk of severe illness and mortality 10 . However, the vaccination strategies also caused some unexpected challenges, because potential vaccine-related deaths negatively influenced the willingness of other people to receive COVID-19 vaccines 11, 12 . The challenges of COVID-19 vaccination in older and middle-aged people, especially cellular immunity, so the immunogenicity and efficacy of vaccines usually remain questionable in older people with frailty, disability, and dementia. Most vaccines used in older people are less immunogenic and effective than those used in younger adults 18 , which results from several factors, e.g., immunosenescence, inflammaging, and altered immune responses to infections and vaccines 19 . Hence, older people need special attention in vaccine development.

For example, influenza virus is transmitted via direct contact, droplets and fomites and particularly increases the burden of disease and mortality in those aged 75 years and older 20,21 . However, the effectiveness of the influenza vaccine was found to be only 29~48% in elderly individuals 22 . The reduced vaccine effectiveness results in a lower prevention rate of hospital admissions due to influenza among older adults (37%, 95% confidence interval (CI) 30-44%) than among younger adults aged 18-64 years (51%, 95% CI 44-58%) 23 . However, the effectiveness of the influenza vaccine to prevent any influenza-associated deaths was shown to be well preserved (74%, 95% CI 44.0-88.4%) for people aged over 65 years and older 24 . The reduced vaccine effectiveness in older adults is related to several factors, such as the virus strain, vaccination rates, seasonal factors, geographic demography, infection history and frailty or multimorbidity. Despite all the abovementioned factors, older age is a key player in vaccine effectiveness 25 . J o u r n a l P r e -p r o o f Current strategies to enhance vaccine immunogenicity and efficacy in older adults include increasing the vaccine dose or adding appropriate adjuvants to trigger immunostimulation, which are common in vaccine development for older people 21,22 . A previous meta-analysis suggested that a high-dose influenza vaccine was consistently more effective than a standard-dose influenza vaccine in reducing influenza cases and influenza-associated clinical complications 26 . On the other hand, the recombinant influenza vaccine using DNA recombination technology to produce influenza hemagglutinin protein in the cell culture instead of growing live influenza virus in embryos has been developed with success. Recombinant influenza vaccines also included high-dose vaccines (three times the influenza antigens). All three abovementioned types of enhanced influenza vaccines induced higher antibody responses than standard-dose vaccines, maintained improvements in immunogenicity and had better protection in people aged over 75 years and those with chronic diseases (heart or lung conditions) 22 .

Similarly, the effects of immune aging have been observed in herpes zoster vaccines. The live attenuated herpes zoster vaccine was the first vaccine developed for herpes zoster prevention, and it significantly and safely increased varicella zoster virus-specific T cell-mediated immunity (51.3% effective rate in preventing herpes zoster; 66.5% effective rate in preventing postherpetic neuralgia) 27 . However, the effectiveness of the herpes zoster vaccine was significantly affected by age. The Shingles Prevention Study 27 demonstrated that the live attenuated zoster vaccine reduced the herpes zoster burden of illness by 61.1% (65.5% in subjects aged 60-69 years; 55.4% in subjects aged ≥70 years), the incidence of clinically significant postherpetic neuralgia by 66.5% (65.7% in subjects aged 60-69 years; 66.8% in subjects aged ≥70 years), and the incidence of herpes zoster by 51.3% (63.9% in subjects aged 60-69 years, but only 37.6% in subjects aged ≥70 years) 28 

The successful development of COVID-19 vaccines has strengthened pandemic control strategies; the WHO aimed to achieve 70% vaccination coverage by mid- 

(1) Older adults with frailty, disability, dementia or living in nursing homes are vulnerable to SARS-CoV-2 infections, but are also susceptible to vaccine-related adverse events. More clinical attentions should be paid and more thorough explanations should be provided to vaccinees and their families.

(2) Limited evidences confirm the safety and efficacy of COVID-19 vaccinations to frail older adults in long-term care settings, all necessary infection controls should be maintained after vaccinations, especially the care staff in long-term care settings.

(3) The completion of a primary series of COVID-19 vaccines with heterologous booster dose in 4-6-month intervals remains the best strategy to reduce the impact of SARS-CoV-2 infections and to obtain immunity against COVID-19 transmission. 

COVID-19) dashboard. World Health Organization

Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population

COVID-19 exposures and infection control among home care agencies

Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks

Delirium and Mortality in Coronavirus Disease 2019 (COVID-19) -A Systematic Review and Meta-analysis

) but has been recommended by an independent vaccine prioritization advisory group to be included in the WHO Solidarity Trial Vaccines (STv)

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines (Basel)

The authors would like to express gratitude to the staff of the Center for Healthy